Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Donaldson, Ashleigh C.![]() |
|
dc.contributor.author | Fuller, Andrea![]() |
|
dc.contributor.author | Meyer, Leith Carl Rodney![]() |
|
dc.contributor.author | Buss, Peter Erik![]() |
|
dc.date.accessioned | 2024-08-14T10:54:59Z | |
dc.date.available | 2024-08-14T10:54:59Z | |
dc.date.issued | 2023-02 | |
dc.description.abstract | Selection of an effective drug combination to immobilise African lions (Panthera leo) requires balancing immobilisation effectiveness with potential side effects. We compared the immobilisation effectiveness and changes to physiological variables induced by three drug combinations used for free-ranging African lions. The lions (12 animals per drug combination) were immobilised with tiletamine-zolazepam-medetomidine (TZM), ketamine-medetomidine (KM) or ketamine-butorphanol-medetomidine (KBM). Induction, immobilisation, and recovery were timed, evaluated using a scoring system, and physiological variables were monitored. The drugs used for immobilisation were antagonised with atipamezole and naltrexone. The quality of induction was rated as excellent for all drug combinations and induction times (mean ± SD) did not differ between the groups (10.54 ± 2.67 min for TZM, 10.49 ± 2.63 min for KM, and 11.11 ± 2.91 min for KBM). Immobilisation depth was similar over the immobilisation period in the TZM and KBM groups, and initially light, progressing to deeper in lions administered KM. Heart rate, respiratory rate and peripheral arterial haemoglobin saturation with oxygen were within the expected range for healthy, awake lions in all groups. All lions were severely hypertensive and hyperthermic throughout the immobilisation. Following antagonism of immobilising drugs, lions immobilised with KM and KBM recovered to walking sooner than those immobilised with TZM, at 15.29 ± 10.68 min, 10.88 ± 4.29 min and 29.73 ± 14.46 min, respectively. Only one lion in the KBM group exhibited ataxia during recovery compared to five and four lions in the TZM and KM groups, respectively. All three drug combinations provided smooth inductions and effective immobilisations but resulted in hypertension. KBM had an advantage of allowing for shorter, less ataxic recoveries. | en_US |
dc.description.department | Centre for Veterinary Wildlife Studies | en_US |
dc.description.department | Paraclinical Sciences | en_US |
dc.description.department | Production Animal Studies | en_US |
dc.description.librarian | am2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | The Copenhagen Zoo. | en_US |
dc.description.uri | http://www.jsava.co.za | en_US |
dc.identifier.citation | Donaldson, A.C., Fuller, A., Meyer, L.C.R. et al. 2023, 'Chemical immobilisation of lions : weighing up drug effectiveness versus clinical effects', Journal of the South African Veterinary Association, vol. 94, no. 1, pp. 23-34. https://DOI.org/10.36303/JSAVA.544 | en_US |
dc.identifier.issn | 2224-9435 (print) | |
dc.identifier.issn | 1019-9128 (online) | |
dc.identifier.other | 10.36303/JSAVA.544 | |
dc.identifier.uri | http://hdl.handle.net/2263/97628 | |
dc.language.iso | en | en_US |
dc.publisher | Medpharm Publications | en_US |
dc.rights | © 2023 The Author(s). Open Access article distributed under the terms of the Creative Commons License [CC BY-NC 3.0]. | en_US |
dc.subject | Butorphanol | en_US |
dc.subject | Cardiorespiratory | en_US |
dc.subject | Induction | en_US |
dc.subject | Medetomidine | en_US |
dc.subject | Lion (Panthera leo) | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject | Ketamine-butorphanol-medetomidine (KBM) | en_US |
dc.subject | Ketamine-medetomidine (KM) | en_US |
dc.subject | Tiletamine-zolazepam-medetomidine (TZM) | en_US |
dc.title | Chemical immobilisation of lions : weighing up drug effectiveness versus clinical effects | en_US |
dc.type | Article | en_US |